Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
Abstract Background Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of adva...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4523-2 |